ArticleDermatology practical & conceptual2025
Persistent Nasal Skin Lesions in Pemphigus Patients and the Role of Methotrexate in Treatment: A Case Series Study.
Article in Dermatology practical & conceptual, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionNasal involvement may happen infrequently, and some lesions may not respond to conventional treatments.
objectivesThe current case series report aimed to describe the characteristics of 10 confirmed pemphigus vulgaris (PV) and pemphigus foliaceus (PF) patients with nasal skin lesions who did not respond to conventional treatment options or relapsed after a while and to evaluate the role of methotrexate in treatment.
methodsData regarding patient demographics, disease type and severity, nasal lesion characteristics, and treatment response were obtained from medical records and direct communication with patients between 2019 and 2023.
resultsEight patients had received intravenous rituximab (RTX) and three had received methotrexate (MTX). Out of the eight pemphigus vulgaris (PV) patients who had undergone RTX treatment, a total of eighteen treatment sessions were carried out. Following RTX therapy, significant improvements were observed in the nasal lesions after eleven (61.1%) sessions, with eight (44.4%) achieving complete resolution within six months. Additionally, three patients who did not have satisfactory results after RTX treatment, received methotrexate, and all experienced complete recovery of their nasal lesions within the same timeframe.
conclusionsAll the patients who benefited from methotrexate had never experienced complete remission of their nasal lesions before. It seems methotrexate can be an eligible choice for recalcitrant cases.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.